WO1999021845A2 - 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases - Google Patents
4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases Download PDFInfo
- Publication number
- WO1999021845A2 WO1999021845A2 PCT/US1998/022809 US9822809W WO9921845A2 WO 1999021845 A2 WO1999021845 A2 WO 1999021845A2 US 9822809 W US9822809 W US 9822809W WO 9921845 A2 WO9921845 A2 WO 9921845A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fused
- amino
- phenyl
- alkyl
- calcd
- Prior art date
Links
- 0 C*(C)(c1cc(C)c(C(c2cccc([N+]([O-])=O)c2)=O)[n]1)c1ccccc1 Chemical compound C*(C)(c1cc(C)c(C(c2cccc([N+]([O-])=O)c2)=O)[n]1)c1ccccc1 0.000 description 18
- CLMRFMZZZPKEHI-UHFFFAOYSA-N CCN(C)C(CC1)=CC=C1Nc1nc(N)c(C(C2C=CC([N+]([O-])=O)=CC2)=O)[s]1 Chemical compound CCN(C)C(CC1)=CC=C1Nc1nc(N)c(C(C2C=CC([N+]([O-])=O)=CC2)=O)[s]1 CLMRFMZZZPKEHI-UHFFFAOYSA-N 0.000 description 1
- QUMXSNCKQFWWIR-OVWCGDOQSA-N C[C@H](C1)N(C(C2CC2)OC(C)(C)C)[C@@H](C)CN1C1C=CC(Nc2nc(N)c(C(c(c(F)ccc3)c3F)=O)[s]2)=CC1 Chemical compound C[C@H](C1)N(C(C2CC2)OC(C)(C)C)[C@@H](C)CN1C1C=CC(Nc2nc(N)c(C(c(c(F)ccc3)c3F)=O)[s]2)=CC1 QUMXSNCKQFWWIR-OVWCGDOQSA-N 0.000 description 1
- LMYRWZFENFIFIT-UHFFFAOYSA-N Cc(cc1)ccc1S(N)(=O)=O Chemical compound Cc(cc1)ccc1S(N)(=O)=O LMYRWZFENFIFIT-UHFFFAOYSA-N 0.000 description 1
- GWLOGZRVYXAHRE-UHFFFAOYSA-N Cc(cc1)ccc1S(NC)(=O)=O Chemical compound Cc(cc1)ccc1S(NC)(=O)=O GWLOGZRVYXAHRE-UHFFFAOYSA-N 0.000 description 1
- AVSYKBPVMQEYTB-UHFFFAOYSA-N NC(C=C1)=CCC1N1CCN(CC(F)(F)F)CC1 Chemical compound NC(C=C1)=CCC1N1CCN(CC(F)(F)F)CC1 AVSYKBPVMQEYTB-UHFFFAOYSA-N 0.000 description 1
- ISPPIHKFSMSJME-UHFFFAOYSA-N Nc1c(C(c2ccccc2[N+]([O-])=O)=O)[s]c(NC2CCCCC2)n1 Chemical compound Nc1c(C(c2ccccc2[N+]([O-])=O)=O)[s]c(NC2CCCCC2)n1 ISPPIHKFSMSJME-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Definitions
- This invention is directed to pharmaceutical compositions containing aminothiazole compounds for inhibiting cyclin-dependent kinases (CDKs), such as CDKl, CDK2, CDK4, and CDK6.
- CDKs cyclin-dependent kinases
- the invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds and to methods of treating malignancies and other disorders by administering effective amounts of such compounds.
- Uncontrolled cell proliferation is the insignia of cancer.
- Cell proliferation in response to various stimuli is manifested by a deregulation of the cell division cycle, the process by which cells multiply and divide.
- Tumor cells typically have damage to the genes that directly or indirectly regulate progression through the cell division cycle.
- CDKs constitute a class of enzymes that play critical roles in regulating the transitions between different phases of the cell cycle, such as the progression from a quiescent stage in G] (the gap between mitosis and the onset of DNA replication for a new round of cell division) to S (the period of active DNA synthesis), or the progression from G 2 to M phase, in which active mitosis and cell-division occur.
- G quiescent stage in G
- S the period of active DNA synthesis
- CDK complexes are formed through association of a regulatory cyclin subunit (e.g., cyclin A, Bl, B2, Dl, D2, D3, and E) and a catalytic kinase subunit (e.g., cdc2 (CDKl), CDK2, CDK4, CDK5, and CDK6).
- a regulatory cyclin subunit e.g., cyclin A, Bl, B2, Dl, D2, D3, and E
- a catalytic kinase subunit e.g., cdc2 (CDKl), CDK2, CDK4, CDK5, and CDK6.
- the D cyclins are sensitive to extracellular growth signals and become activated in response to mitogens during the Gi phase of the cell cycle.
- CDK4/cyclin D plays an important role in cell cycle progression by phosphorylating, and thereby inactivating, the retinoblastoma protein (Rb). Hypophosphorylated Rb binds to a family of transcriptional regulators, but upon hyperphosphorylation of Rb by CDK4/cyclin D, these transcription factors are released to X activate genes whose products are responsible for S phase progression.
- Rb phosphorylation and inactivation by CDK4/cyclin D permit passage of the cell beyond the restriction point of the Gi phase, whereupon sensitivity to extracellular growth or inhibitory signals is lost and the cell is committed to cell division.
- CDK2/cyclin E can also regulate progression into S phase through a parallel pathway that is independent of Rb phosphorylation (see Lukas et al., "Cyclin E-induced S Phase Without Activation of the pRb/E2F Pathway," Genes and Dev., vol. 11 (1997), pp. 1479-1492).
- CDK4-specific inhibitors of the pl6 family frequently have deletions and mutations in familial melanoma, gliomas, leukemias, sarcomas, and pancreatic, non-small cell lung, and head and neck carcinomas (see Nobori et al, "Deletions of the Cyclin-Dependent Kinase-4 Inhibitor Gene in Multiple Human Cancers," Nature, vol. 368
- cyclin E has also been observed in a wide variety of solid tumors, and elevated cyclin E levels have been correlated with poor prognosis.
- the cellular levels of the CDK inhibitor p27 which acts as both a substrate and inhibitor of CDK2/cyclin E, are abnormally low in breast, colon, and prostate cancers, and the expression levels of p27 are inversely correlated with the stage of disease (see Loda et al, "Increased Proteasome-dependent Degradation of the Cyclin-Dependent Kinase Inhibitor p27 in Aggressive Colorectal Carcinomas," Nature Medicine, vol. 3 (1997), pp. 231- 234).
- the p21 proteins also appear to transmit the p53 tumor-suppression signal to the CDKs; thus, the mutation of p53 in approximately 50% of all human cancers may indirectly result in deregulation of CDK activity.
- Flavopiridol displays modest selectivity for inhibition of CDKs over other kinases, but inhibits CDK4, CDK2, and CDKl equipotently, with IC 50 s in the 0.1-0.3 ⁇ M range.
- Flavopiridol is currently in Phase II clinical trials as an oncology chemotherapeutic (Sedlacek et al., "Flavopiridol (L86-8275; NSC 649890), A New Kinase Inhibitor for Tumor Therapy," Int. J. Oncol, vol. 9 (1996), pp. 1143-1168).
- Analogs of flavopiridol are the subject of other publications, for example, U.S. Patent No.
- CDK4 may serve as a general activator of cell division in most cells, and because complexes of
- CDK4/cyclin D and CDK2/cyclin E govern the early Gi phase of the cell cycle, there is a need for effective and specific inhibitors of CDK4 and/or CDK2 for treating one or more types of tumors.
- one object of the invention is to attain compounds and drug compositions that inhibit the activity of one or more CDKs, such as CDK2, CDK4, and/or CDK6, or cyclin complexes thereof.
- a further object is to provide an effective method of treating cancer indications through CDK inhibition, preferably through inhibition of CDK4 or CDK4/D-type cyclin complexes and/or CDK2 or CDK2/E-type cyclin complexes.
- Another object is to achieve pharmaceutical compositions containing compounds effective to block the transition of cancer cells into their proliferative phase.
- compositions comprising:
- R 1 is a substituted or unsubstituted group selected from: C ⁇ _ -alkyl
- carbocyclic or heterocyclic cycloalkyl which may be monocyclic or fused or non-fused polycyclic (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl) or heterocycloalkyl, which may be monocyclic or fused or non-fused polycyclic (e.g., pyrrolidinyl, piperidinyl, morpholinyl); carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic aryl (e.g., phenyl, naphthyl, pyrrolyl, indolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, pyrazolyl, pyridinyl, quinolinyl, isoquinoliny
- halogen e.g., chloro, iodo, bromo, or fluoro
- haloalkyl e.g., trifluoromethyl
- carbocyclic cycloalkyl which may be monocyclic or fused or non-fused polycyclic (e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), or a heterocycloalkyl, which may be monocyclic or fused or non-fused polycyclic (e.g., pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, or thiazinyl); carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic aryl (e.g., phenyl, naphthyl, pyrrolyl, indolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, pyrazolyl, pyridiny
- compositions comprising:
- R 1 is selected from:
- halogen e.g., chloro, iodo, bromo, or fluoro
- haloalkyl e.g., trifluoromethyl
- C ⁇ _ -alkyl C ⁇ - 6 -alkenyl; C]. 6 -alkynyl; hydroxyl; C ⁇ .
- carbocyclic cycloalkyl which may be monocyclic or fused or non-fused polycyclic (e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), or a heterocycloalkyl, which may be monocyclic or fused or non-fused polycyclic (e.g., pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, or thiazinyl); carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic aryl (e.g., phenyl, naphthyl, pyrrolyl, indolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, pyrazolyl, pyridiny
- compositions are useful as inhibitors of mammalian CDK/cyclin complexes, insect
- compositions are also useful for controlling proliferation, differentiation, and/or apoptosis.
- the invention is directed to pharmaceutical compositions containing pharmaceutically effective amounts of cell- cycle control agents.
- the invention is directed to potent cell-cycle control agents where R 2 in Formula I is an ortho-substituted aryl ring structure (e.g., o-substituted phenyl).
- Particularly preferred among such agents are those in which R" is an o-disubstituted phenyl.
- the invention further relates to methods of using cell-cycle control agents for treating diseases or disorders mediated by CDK inhibition, especially those mediated by CDK4 and/or CDK2 inhibition. More particularly, the invention is directed to methods of treating malignancies or cancer-type disorders by administering a pharmaceutical composition comprising a cell-cycle control agent. Additionally, the invention relates to the use of cell-cycle control agents to prevent or treat mycotic infections.
- compositions each comprising:
- R 1 is a substituted or unsubstituted group selected from: C ⁇ - 6 -alkyl; C ⁇ - 6 -alkenyl; C ⁇ _ 6 -alkynyl; ⁇ -alkoxyl; carbocylic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; carbonyl; ether; (C ⁇ _ 6 - alkyl)-carbonyl; (C ⁇ . 6 -alkyl)-aryl; (C ⁇ _ 6 -alkyl)-cycloalkyl; (C ⁇ .
- R 6 is a substituted or unsubstituted, carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, ring structure; where each optional substituent for R 1 and R " is independently a halogen; haloalkyl; Cj- ⁇ -alkyl; C ⁇ _ 6 -alkenyl; C ⁇ ..
- each optional substituent for R 1 and R 2 may be independently selected from, in addition to the above-identified groups, the following groups: oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; and carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl.
- substituents may optionally be further substituted with a substituent selected from such groups.
- Examples for the moiety R 1 include substituted or unsubstituted aryl and alkyl, such as phenyl, pyridyl, benzimidazole, benzyl, and C ⁇ _ 6 -alkyl.
- these groups have one or more substituents selected from: halogen; oxygen; haloalkyl; C ⁇ . 6 -alkyl; cycloalkyl; heterocycloalkyl; aryl; hydroxyl; C ⁇ . 6 alkoxyl; amino; nitro thioether; cyano; amido; carboxyl; sulfonamido; ketone; aldehyde; and ester.
- R 1 phenyl groups substituted by an alkylamine or pyridine group having optional substituents selected from the group described in the above paragraph for R 1 .
- the alkylamine substitutent may be a 5- to 7-membered heterocycloalkyl optionally containing, in addition to the nitrogen ring atom, one or more heteroatoms selected from N, O and S.
- R groups include phenyl substituted in the para position with a heterocycloalkyl, for example piperidinyl, piperazinyl, thiazinyl, or morpholinyl, or a pyridyl group.
- a heterocycloalkyl for example piperidinyl, piperazinyl, thiazinyl, or morpholinyl, or a pyridyl group.
- R , 1 groups include phenyl groups substituted with carbonyl or sulfonamide moieties, wherein the carbonyl carbon and sulfonamide nitrogen are optionally further substituted.
- R 1 groups include phenyl groups substituted with carbonyl or sulfonamide moieties, wherein the carbonyl carbon and sulfonamide nitrogen are optionally further substituted.
- R 3 is selected from C ⁇ -C 6 alkyl, C ⁇ -C 6 alkoxy, aryl, aryloxy, and amine.
- R 1 examples include substituted or unsubstituted phenyl, alkylbenzyl, alkyl, benzyl carboxyl ester, benzyloxyphenyl, dimethylaminophenyl, pyridinyl, ' phenethyl, alkylcarboxyl, alkylpiperidinyl, phenylamino, cyclohexyl, Benzylcarboxylalkyl, benzylnitro, phenyl-alkoxyl, ethyl benzoate, benzyl carboxyl, alkylbenzoimidazole, benzoimidazole, benzyldimethylamino, pyridinyl-sulfanyl, cyanobenzyl, and phenyl sulfamyl.
- R ⁇ in Formula I is a bulky group such as a substituted or unsubstituted carbocyclic or heterocyclic monocycle, or a substituted or unsubstituted fused or non-fused carbocyclic or heterocyclic polycycle. More preferably, R " is a substituted (carbo or poly)-(monocycle or polycycle); even more preferably, R " is such a cyclic ring structure bearing a substituent at the position adjacent or vicinal to the point of attachment (to the core structure).
- preferred species for R " include an ortho-substituted aromatic ring structure such as o-substituted phenyl or thienyl, or a 1 ,2-substituted cycloalkyl or cycloalkenyl ring structure such as 2-substituted cyclopent-1-enyl.
- R 2 include substituted or unsubstituted: o-halophenyl (e.g., -fluorophenyl, o- chlorophenyl, o-iodophenyl, or ⁇ -bromophenyl), o-nitrophenyl, o-aminophenyl, o-C ⁇ _ 6 - alkylphenyl, o-C ⁇ _ 6 -alkoxyphenyl (e.g., o-methoxyphenyl or o-ethoxyphenyl), o-C ⁇ _ 6 - alkoxybenzothiophenyl, o-methylthiophenyl, benzonitrile, and carboxybenzyl.
- o-halophenyl e.g., -fluorophenyl, o- chlorophenyl, o-iodophenyl, or ⁇ -bromophenyl
- o-nitrophenyl e.g.
- R ⁇ also include ortho-disubstituted aryls, for example, 2,6- dihalophenyl (e.g., 2,6-difluorophenyl) and 2-halo-6-trifluoromethylphenyl (e.g., 2-fluoro-6- trifluoromethylphenyl).
- ortho-disubstituted aryls for example, 2,6- dihalophenyl (e.g., 2,6-difluorophenyl) and 2-halo-6-trifluoromethylphenyl (e.g., 2-fluoro-6- trifluoromethylphenyl).
- R " is a 1 ,2-substituted cyclic ring structure, optionally having one or more additional substituents, such as an ortho-substituted aryl having another substituent at the para position, have been surprisingly found to be potent CDK inhibitors.
- Particularly preferred examples of compounds of Formula I include:
- Another preferred compound of Formula I is:
- compositions according to the invention may, alternatively or in addition to a compound of the Formula I, comprise as an active ingredient a pharmaceutically acceptable salt of a compound of the Formula I, or a prodrug or pharmaceutically active metabolite of such a compound or salt.
- a pharmaceutically acceptable salt of a compound of the Formula I or a prodrug or pharmaceutically active metabolite of such a compound or salt.
- Such compounds, salts, prodrugs, and metabolites are sometimes referred to herein collectively as "cell-cycle control agents.”
- compositions in accordance with the invention inhibit the kinase activity of CDK cyclin complexes, such as those active in the Go or G ⁇ stage of the cell cycle, e.g., CDK2, CDK4, and/or CDK6 complexes.
- Preferred compositions of the invention contain cell-cycle control agents having an inhibition constant against CDK4 or a CDK4/D-type cyclin complex of about 1 ⁇ M or less, more preferably of about 500 nM or less, even more preferably of about 200 nM or less, and most preferably of about 100 nM or less.
- Especially preferred compounds of the invention include those having a CDK4/cyclin D3 inhibition constant (K, CDK4/D3) of about 100 nM or less.
- compositions of the invention contain cell-cycle control agents having an inhibition constant against CDK2 or a CDK2/E-type cyclin complex of about 1 ⁇ M or less, more preferably of about 500 nM or less, even more preferably of about 200 nM or less, and most preferably of about 100 nM or less.
- Certain compounds of the Formula I may exist in various stereoisomeric or tautomeric forms.
- the present invention encompasses all such CDK-inhibiting compounds, including active compounds in the form of essentially pure enantiomers, racemic mixtures, and tautomers.
- pharmaceutically acceptable means pharmacologically acceptable and substantially non-toxic to the subject being administered the cell-cycle control agent.
- salts include conventional acid-addition salts or base-addition salts formed from suitable non-toxic organic or inorganic acids or inorganic bases.
- Exemplary acid- addition salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid, and nitric acid, and those derived from organic acids such as p-toluenesulfonic acid, methanesulfonic acid, ethane- disulfonic acid, isethionic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, 2-acetoxybenzoic acid, acetic acid, phenylacetic acid, propionic acid, glycolic acid, stearic acid, lactic acid, malic acid, tartaric acid, ascorbic acid, maleic acid, hydroxymaleic acid, gluta
- Exemplary base-addition salts include those derived from ammonium hydroxides (e.g., a quaternary ammonium hydroxide such as tetramethylammonium hydroxide), those derived from inorganic bases such as alkali or alkaline earth-metal (e.g., sodium, potassium, lithium, calcium, or magnesium) hydroxides, and those derived from organic bases such as carbonates, bicarbonates, amines, benzylamines, piperidines, and pyrrolidines.
- ammonium hydroxides e.g., a quaternary ammonium hydroxide such as tetramethylammonium hydroxide
- inorganic bases such as alkali or alkaline earth-metal (e.g., sodium, potassium, lithium, calcium, or magnesium) hydroxides
- organic bases such as carbonates, bicarbonates, amines, benzylamines, piperidines, and pyrrolidines.
- prodrug refers to a metabolic precursor of a compound of the Formula I (or a salt thereof) that is pharmaceutically acceptable.
- a prodrug may be inactive when administered to a subject but is converted in vivo to an active compound of the Formula I.
- active metabolite refers to a metabolic product of a compound of the Formula I that is pharmaceutically acceptable and effective.
- Prodrugs and active metabolites of compounds of the Formula I may be determined using techniques known in the art.
- Cell-cycle control agents in accordance with the invention are useful as pharmaceuticals for treating proliferative disorders in mammals, especially humans, marked by unwanted proliferation of endogenous tissue.
- Compounds of the Formula I may be used for treating subjects having a disorder associated with excessive cell proliferation, e.g., cancers, psoriasis, immunological disorders involving undesired proliferation of leukocytes, and restenosis and other smooth-muscle disorders. Furthermore, such compounds may be used to prevent de- differentiation of post-mitotic tissue and/or cells.
- compositions or preparations of the invention comprise a pharmaceutically acceptable carrier and an effective amount of at least one cell-cycle control agent.
- effective amount means an amount that significantly inhibits proliferation, and/or prevents de-differentiation of a eukaryotic cell, e.g., a mammalian, insect, plant, or fungal cell, and is effective for the indicated utility, e.g., specific therapeutic treatment.
- the specific dosage amount of a cell-cycle control agent being administered to obtain therapeutic or inhibitory effects may be determined in a manner known in the art according to the particular circumstances surrounding the case, including, e.g., the specific agent being administered, the route of administration, the condition being treated, and the subject or host being treated.
- An exemplary total daily dose of a cell-cycle control agent which may be administered in single or multiple doses, contains a dosage level of from about 0.01 mg/kg body weight to about 50 mg/kg body weight.
- the cell-cycle control agents of the invention may be administered by any of a variety of suitable routes, such as orally, rectally, transdermally, subcutaneously, intravenously, intramuscularly, or intranasally.
- suitable routes such as orally, rectally, transdermally, subcutaneously, intravenously, intramuscularly, or intranasally.
- the cell-cycle control agents are preferably formulated into compositions suitable for the desired routes before being administered.
- a pharmaceutical composition or preparation according to the invention comprises an effective amount of a cell-cycle control agent and a pharmaceutically acceptable carrier, such as a diluent or excipient for the agent.
- a pharmaceutically acceptable carrier such as a diluent or excipient for the agent.
- the carrier may be a solid, semi- solid, or liquid material acting as a vehicle, excipient, or medium for the active ingredient(s).
- Compositions according to the invention may be made by admixing the active ingredient(s) with a carrier, or diluting it with a carrier, or enclosing or encapsulating it within a carrier, which may be in the form of a capsule, sachet, paper container, or the like.
- Exemplary ingredients in addition to one or more cell-cycle control agents and any other active ingredients, include Avicel (microcrystalline cellulose), starch, lactose, calcium sulfate dihydrate, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid, peanut oil, olive oil, glyceryl monostearate, Tween 80 (polysorbate 80), 1,3-butanediol, cocoa butter, beeswax, polyethylene glycol, propylene glycol, sorbitan monostearate, polysorbate 60, 2-octyldodecanol, benzyl alcohol, glycine, sorbic acid, potassium sorbate, disodium hydrogen phosphate, sodium chloride, and water.
- Avicel microcrystalline cellulose
- starch lactose
- calcium sulfate dihydrate terra alba
- sucrose talc
- gelatin agar
- compositions may be prepared in any of a variety of forms suitable for the desired mode of administration.
- pharmaceutical compositions may be prepared in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as solids or in liquid media), ointments (e.g., containing up to 10% by weight of a cell-cycle control agent), soft-gel and hard-gel capsules, suppositories, sterile injectable ., solutions, sterile packaged powders, and the like.
- a pharmaceutical composition according to the invention comprises a cell-cycle control agent and, optionally, one or more other active ingredients, such as a known antiproliferative agent that is compatible with the cell-cycle control agent and suitable for the indication being treated.
- a pharmaceutical composition of the invention includes an effective amount of a cell-cycle control agent of the Formula I as an active ingredient.
- the title compound was prepared in a manner like that described for Example C(l).
- the product from 4-chlorophenethyl isothiocyanate and 2-bromo-2'-methoxy-acetophenone was extracted with 10% i-PrOH/CHCl3.
- the resultant solid was washed with Et2 ⁇ to give an ivory solid in 49% yield, mp 150-151°C.
- 5-Bromoacetyl-4-methyl- lH-imidazole which has the structural formula was first prepared as follows. Bromine (0.40 mL, 7.77 mmol) was added dropwise to a solution of 5-acetyl-4-mefhyl-lH-imidazole (964 mg, 7.77 mmol; LaMattina et al, J. Org. Chem., vol. 48 (1983), pp. 897-898) in ⁇ OAc (20 mL). After two days, the ⁇ OAc was removed in vacuo and the residue partitioned with C ⁇ 2 C1 2 and sat. aq. NaHCO 3 .
- Example C(l) The title compound was prepared essentially as described for Example C(l).
- the product from 4-isothio-cyanato-benzoyl-DL-homoserine lactone and 2-bromoacetyl-3-methyl- thiophene (from Example C(19)) was extracted into 10% i-PrOH/CHCl3. Flash column chromatography with 2-3-4-5-6% MeOH/CH2 ⁇ 2 stepwise gradient gave a yellow solid in 43% yield, mp 162-3°C.
- Example C(l) The title compound was prepared essentially as described for Example C(l).
- the product from ethyl dl-3-isothiocyanato-butyrate and 2-bromoacetyl-3-methyl-thiophene (from Example C(19)) was extracted with 10% i-PrOH/ CHCI3. Flash column chromatography with 3% MeOH/CH2Cl2 gave a yellow solid in 45% yield, mp 129-30°C.
- Example C(l) The title compound was prepared in a manner analogous to that used in Example C(l). 4-Isothiocyanato-benzenesulfonamide and 2-bromoacetyl-3-methyl-thiophene (from Example C(19)) provided a yellow solid in 69% yield, mp 284.5-286.0 ° C.
- 2-Bromo-2',6'-dichloro-acetophenone which has the structural formula was prepared as follows. To 2',6'-dichloroacetophenone (1.0 g, 5.30 mmol) in HOAc (5 mL) ⁇ was added dropwise bromine (272 ⁇ l, 5.30 mmol). The mixture was heated at 90°C for 1 hour, then diluted with ice-water and partitioned between ether and sat aq NaHCO 3 .
- 2-(4-Nitro-phenyl)-lH-im idazole which has the structural formula was first prepared as follows. To a solution of 2-phenylimidazole (5.00 g, 34.7 mmol) in cone. H 2 SO 4 (20 mL) at 0°C was added a solution of cone. HNO 3 (2.2 mL, 35 mmol) in cone. H 2 SO 4 (5 mL). The resultant brown mixture was stirred at 0°C for 2 hours and quenched with crushed- ice. A pale white precipitate formed, which was filtered. The filtrate was brought to pH 9 with 2N NaOH.
- H 3 C X ⁇ ,HBr was first prepared as follows. 4-Acetyl-3,5-dimethylpyridine (500 mg, 3.36 mmol; Kutney et al., Can. J. Chem., vol. 41 (1963), pp. 695-702) was dissolved in 30% HBr in acetic acid (1 mL), heated to 70°C, and treated with a mixture of bromine (0.17 mL, 3.36 mmol) in 30% HBr in acetic acid (0.5 mL). After 2 hours, the mixture was allowed to cool to ambient temperature and ether (8 mL) was added. The resultant precipitate was filtered off, rinsed with ether (2x), and dried to afford 1.03 g (100%) of a pu ⁇ le solid, mp 222-225°C, that was used without further purification.
- 2-Bromo-2',6'-dimethyl-acetophenone which has the structural formula was prepared in a manner analogous to 2-bromo-2'-iodo-acetophenone, see Example C(12).
- 2',6'-dimethylacetophenone (1.50 g, 10.1 mmol) provided 2.04 g (89% yield) of clear oil, which was used without further purification.
- Example C(l) The title compound was prepared in a manner analogous to that used in Example C(l). 4-(4-Isothiocyanato-phenyl)-mo ⁇ holine (from Example C(54)) and 2-bromo-2',6'-dimethyl- acetophenone (from Example C(60)) provided a brown solid in 23% yield, mp 221-223 C.
- Example C(l) The title compound was prepared essentially as described for Example C(l). 4- Isothiocyanato-benzenesulfonamide and 2S-bromoacetyl-N-carbobenzyloxy-pyrrolidine (see Example C(64)) provided a solid that was purified via column chromatography with 5%
- 2,2'-Dibromo-6'-methyl-acetophenone which has the structural formula was prepared in a manner analogous to 2-bromo-2'-iodo-acetophenone, see Example C(12). Crude 2'-bromo-6'-methyl-acetophenone (1.00 g, 4.69 mmol) provided 1.48 g of yellow oil, which was used without further purification.
- 2-Acetyl-3,5-dibromo-thiop hene which has the structural formula , was first prepared as follows. To a solution of 2, 4-dibromothiophene (2.0 g, 8.27 mmol) and acetyl chloride (0.82 mL, 11.6 mmol) in ether (3 mL) was added portionwise A1C1 3 (1.5 g, 1 1.2 mmol). After 4 hours, another portion of acetyl chloride and AICI 3 were added, the mixture was refluxed for 1 hour and allowed to cool. The reaction was carefully quenched with ice and extracted with ether.
- Example C(l) The title compound was prepared in a manner analogous to that used in Example C(l). 4-Isothiocyanato-benzenesulfonamide and 2-bromoacetyl-3,5-dibromo-thiophene (from Example C(72)) provided a yellow powder in 41% yield, mp 254-255 ° C.
- HO f H3 o N ⁇ 5 was first made as follows. A fresh solution of NaOH (3.86 g, 96.5 mmol) in water (20 mL) was added to a solution of ethyl l,5-dimethyl-lH-imidazole-4-carboxylate (5.39 g, 32.0 mmol; Ohno et al, Chem. Pharm. Bull, vol. 42 (1994), pp. 1463-1473) in EtOH (20 mL). After 5 hours, the mixture was cooled to 0 C, and acidified with 38% HCl to pH 3-4. The resultant white solid was filtered off, washed with small amount of cold EtOH:H 2 O (1: 1), and 1 dried under high vacuum to give 3.51 g (78%) of white solid, which was used without further purification.
- t e structura ormu a o was next prepared as follows. To a mixture of 1,5- dimethyl-lH-imid.azole-4-carboxylic acid (2.01 g, 14.4 mmol) in DMF (20 mL) was added O-(7- azabenzotriazol-l-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU; 6.00 g, 15.8
- 2-Acetyl-3-methyl-5-nitro-thiophene which has the structural formula was first prepared as follows. 2-Bromo-3-methyl-5-nitro-thiophene (5.17 g, 23.3 mmol; Spinelli et al, J. Chem. Soc. Perkin Trans. 2, (1975), pp. 620-622), tributyl (l-ethoxyvinyl)tin(IV) (8.65 mL, 25.6 mmol), and dichlorobis-(triphenylphosphine) palladium(II) (163 mg, 0.23 mmol) in toluene (10.5 mL) was heated under Ar° at 100°C for 2.5 hours.
- Example C(12) 2-Acetyl-3-methyl-5-nitro-thiophene (230 mg, 1.24 mmol) provided 330 mg of a cloudy yellow oil, which contained a trace amount of dibrominated byproduct by NMR, which was used without further purification.
- 3'-Amino-2',6'-dichloro-acetophenone which has the structural formula , was first prepared as follows. To a solution of SnC • 2 H2O (7.70 g, 34.2 mmol) in 6N aq HCl (20 mL) was added 2',6'-dichloro-3'-nitro-acetophenone (4.00 g, 17.1 mmol; Breslin, et al., J. Med. Chem., vol. 38 (1995), pp. 771-793). The resultant mixture was heated at reflux for 5 hours, allowed to cool, and carefully treated with anhydrous Na CO . The resultant white precipitate was filtered off and washed with CHCI3.
- o ci was next prepared as follows. To a solution of 3'-amino-2',6'-dichloro- acetophenone (2.40 g, 1 1.8 mmol) in glacial acetic acid (25 mL) was added acetic anhydride (5.56 mL, 58.8 mmol). The resultant mixture was heated at reflux for 2 hours, allowed to cool, and diluted with ether (100 mL). The organic layer was washed with H 2 O (2 x 50 mL), dried over MgSO 4 , concentrated in vacuo, and azeotroped with n-heptane to give 2.3 g of a pale white solid, which was used without further purification.
- Example C(l) The title compound was prepared in a manner analogous to that used in Example C(l). 4-(4-Isothiocyanato-phenyl)-mo ⁇ holine (from Example C(54)) and 2-bromoacetyl-3-methyl- biphenyl (from Example C(67)) provided a yellow solid in 29% yield, mp 125-35°C.
- Example C(l) The title compound was prepared in a manner analogous to that used in Example C(l).
- 4-(4-Isothiocyanato-phenyl)-mo ⁇ holine (from Example C(54)) and 2,2' -dibromo-6' -methyl - acetophenone (from Example C(66)) provided a crude solid, which was triturated with MeOH/CHCl 3 to furnish a yellow solid in 22% yield, mp 105-125 ° C.
- Example C(l) The title compound was prepared in a manner analogous to that used in Example C(l). 4-Isothiocyanato-benzenesulfonamide and 2-bromo-2', 6' -difluoro-acetophenone (from Example C(79)) provided light yellow crystals in 69% yield, mp 258-260°C.
- Example C(l) The title compound was prepared essentially as described for Example C(l). 4- Isothiocyanato-benzoyl-DL-homoserine lactone and 4-bromoacetyl-3,5-dichloropyridine (from Example C(63)) gave a product which was purified via column chromatography with 10% 1 MeOH/CHCl3 as eluant to provide an amo ⁇ hous yellow solid, 203 mg (79%), that decomposed above 150°C.
- Acetyl-2,5-dichlorothiophene (2.0 g, 10.2 mmol) provided 2.9 g (100% yield) of yellow oil, o which was used without further purification.
- 2,4,6-Trichloroacetophenone which has the structural formul was first prepared as follows. Adapted from a procedure by Reynolds et al.. Org. Syn. Coll., vol. IV (1963), pp. 708-710. To Mg turnings (283 mg, 11.3 mmol) and EtOH (0.25 mL) was added CC1 4 (11 ⁇ L). The ensuing reaction subsided, before a solution of diethyl malonate (1.71 mL, 1 1.33 mmol) in EtOH (0.91 mL) was added at a rate to sustain reaction. After 30 min, the mixture was refluxed to consume Mg for one hour, then allowed to cool.
- Example C(12) Crude 2',4',6'-trichloroacetophenone afforded 1.27 g (94%) of gold crystals that were used without further purification (previously described in Baker et al., J. Chem. Soc.
- Example C(79) provided a crude product, which was extracted with 10% i-PrOH/CHCl 3 and purified via column chromatography with 5% MeOH/CHCl 3 to afford an amo ⁇ hous yellow powder in 41% yield, that decomposed above 200°C.
- Example C(l) The title compound was prepared in a manner analogous to that used in Example C(l). 4-Isothiocyanato-N, N-dimethyl-benzenesulfonamide and 2-bromo-2',6'-difluoro-acetophenone (from Example C(79)) provided a crude brown solid that recrystallized from EtOH to give light- brown crystals in 52% yield, mp 240-242°C.
- 1,2-diamine provided a brown oil in 75% crude yield, which was used without further purification.
Priority Applications (22)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR9815200-9A BR9815200A (pt) | 1997-10-27 | 1998-10-27 | Composto, composição farmacêutica e método de tratamento de uma doença ou distúrbio mediado pela inibição de cdk4 ou um complexo de cdk4/ciclina |
EA200000464A EA003527B1 (ru) | 1997-10-27 | 1998-10-27 | Замещенные 4-аминотиазолы в качестве ингибиторов циклинзависимых киназ |
SI9820068A SI20324A (sl) | 1997-10-27 | 1998-10-27 | Substituirane 4-amino-tiazol-2-il spojine kot cdk inhibitorji |
ROA200000423A RO119463B1 (ro) | 1997-10-27 | 1998-10-27 | Derivaţi de 4-aminotiazol şi utilizarea lor ca inhibitori ai cdk |
IL13557498A IL135574A0 (en) | 1997-10-27 | 1998-10-27 | Substituted 4-amino-thiazol-2-yl compounds as cdk inhibitors |
HU0004512A HUP0004512A3 (en) | 1997-10-27 | 1998-10-27 | 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases |
APAP/P/2000/001795A AP1445A (en) | 1997-10-27 | 1998-10-27 | Substituted 4-amino-thiazol-2-yl compounds as CDKs inhibitors. |
KR1020007004392A KR20010082501A (ko) | 1997-10-27 | 1998-10-27 | 4-아미노티아졸 유도체, 그 제조방법 및 싸이클린-의존성키나아제의 억제제로서의 이용방법 |
UA2000042107A UA66810C2 (uk) | 1997-10-27 | 1998-10-27 | Похідні 4-амінотіазолу та композиції на їх основі як інгібітори циклінозалежних кіназ |
DE69833223T DE69833223T2 (de) | 1997-10-27 | 1998-10-27 | 4-aminothiazol derivate, deren herstellung und deren verwendung als inhibitoren cyclin-abhängiger kinasen |
NZ503788A NZ503788A (en) | 1997-10-27 | 1998-10-27 | 4-aminothiazole derivatives and their use as inhibitors of cyclin-dependent kinases |
CA002306082A CA2306082A1 (en) | 1997-10-27 | 1998-10-27 | Substituted 4-amino-thiazol-2-y compounds as cdks inhibitors |
AU13664/99A AU738792B2 (en) | 1997-10-27 | 1998-10-27 | 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases |
EEP200000289A EE200000289A (et) | 1997-10-27 | 1998-10-27 | Asendatud 4-amino-tiasool-2-üüli ühendid kui tsükliinisõltuvusega kinaaside inhibiitorid |
SK521-2000A SK5212000A3 (en) | 1997-10-27 | 1998-10-27 | 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases |
JP2000517957A JP2004500304A (ja) | 1997-10-27 | 1998-10-27 | 4−アミノチアゾ−ル誘導体、その製造法およびサイクリン依存キナ−ゼ抑制剤としての使用法 |
EP98957393A EP1056732B1 (en) | 1997-10-27 | 1998-10-27 | 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases |
NO20001955A NO20001955L (no) | 1997-10-27 | 2000-04-14 | Substituerte 4-amino-tiazol-2-yl forbindelser som inhibitorer av cyclinavhengige kinaser |
HR20000222A HRP20000222A2 (en) | 1997-10-27 | 2000-04-17 | SUPSTITUTED 4-AMINO-THIAZOL-2-yl COMPOUNDS AS CDK INHIBITORS |
IS5462A IS5462A (is) | 1997-10-27 | 2000-04-19 | Setin 4-amínó-þíazol-2-yl efnasambönd sem hindrarfyrir CDK |
LVP-00-51A LV12592B (en) | 1997-10-27 | 2000-05-03 | COMPLETE 4-AMINOTIAZOL COMPOUNDS AS CYCLINCINARY CHINESE INHIBITORS |
BG104478A BG64195B1 (bg) | 1997-10-27 | 2000-05-26 | Производни на 4-аминотиазол, тяхното получаване и използване като инхибитори на циклинзависими кинази |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6363497P | 1997-10-27 | 1997-10-27 | |
US60/063,634 | 1997-10-27 | ||
US6366697P | 1997-10-28 | 1997-10-28 | |
US60/063,666 | 1997-10-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999021845A2 true WO1999021845A2 (en) | 1999-05-06 |
WO1999021845A3 WO1999021845A3 (en) | 1999-08-19 |
Family
ID=26743609
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/022809 WO1999021845A2 (en) | 1997-10-27 | 1998-10-27 | 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases |
Country Status (34)
Country | Link |
---|---|
US (2) | US6569878B1 (xx) |
EP (1) | EP1056732B1 (xx) |
JP (1) | JP2004500304A (xx) |
KR (1) | KR20010082501A (xx) |
CN (1) | CN1158269C (xx) |
AP (1) | AP1445A (xx) |
AT (2) | ATE332896T1 (xx) |
AU (1) | AU738792B2 (xx) |
BG (1) | BG64195B1 (xx) |
BR (1) | BR9815200A (xx) |
CA (1) | CA2306082A1 (xx) |
DE (2) | DE69833223T2 (xx) |
EA (1) | EA003527B1 (xx) |
EE (1) | EE200000289A (xx) |
ES (2) | ES2267873T3 (xx) |
GE (1) | GEP20032896B (xx) |
HR (1) | HRP20000222A2 (xx) |
HU (1) | HUP0004512A3 (xx) |
ID (1) | ID24372A (xx) |
IL (1) | IL135574A0 (xx) |
IS (1) | IS5462A (xx) |
LT (1) | LT4855B (xx) |
LV (1) | LV12592B (xx) |
NO (1) | NO20001955L (xx) |
NZ (1) | NZ503788A (xx) |
OA (1) | OA11352A (xx) |
PL (1) | PL342447A1 (xx) |
RO (1) | RO119463B1 (xx) |
SI (1) | SI20324A (xx) |
SK (1) | SK5212000A3 (xx) |
TR (1) | TR200001081T2 (xx) |
UA (1) | UA66810C2 (xx) |
WO (1) | WO1999021845A2 (xx) |
YU (1) | YU22400A (xx) |
Cited By (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000075120A1 (en) * | 1999-06-04 | 2000-12-14 | Agouron Pharmaceuticals, Inc. | Diaminothiazoles and their use for inhibiting protein kinases |
WO2001014353A1 (en) * | 1999-08-12 | 2001-03-01 | Pharmacia Italia, S.P.A. | Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents |
US6214852B1 (en) | 1998-10-21 | 2001-04-10 | Bristol-Myers Squibb Company | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
US6235764B1 (en) | 1998-06-04 | 2001-05-22 | Pfizer Inc. | Isothiazole derivatives useful as anticancer agents |
EP1122242A1 (en) * | 1998-09-22 | 2001-08-08 | Yamanouchi Pharmaceutical Co. Ltd. | Cyanophenyl derivatives |
WO2001056567A1 (en) * | 2000-02-04 | 2001-08-09 | Novo Nordisk A/S | 2,4-diaminothiazole derivatives and their use as glycogen synthase kinase-3 (gsk-3) inhibitors |
WO2001085726A1 (en) * | 2000-05-10 | 2001-11-15 | Lg Life Sciences Ltd. | Indazoles substituted with 1,1-dioxoisothiazolidine useful as inhibitors of cell proliferation |
WO2002012250A2 (en) * | 2000-08-09 | 2002-02-14 | Agouron Pharmaceuticals, Inc. | Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases |
US6392053B2 (en) | 1999-12-15 | 2002-05-21 | Bristol-Myers Squibb Company | Process for preparing arylacetylaminothiazoles |
US6414156B2 (en) | 1998-10-21 | 2002-07-02 | Bristol-Myers Squibb Company | Process for preparing azacycloalkanoylaminothiazoles |
WO2002057240A1 (en) * | 2000-12-22 | 2002-07-25 | Ortho Mc Neil Pharmaceutical, Inc. | Substituted triazole diamine derivatives as kinase inhibitors |
WO2002057261A2 (en) * | 2001-01-22 | 2002-07-25 | F. Hoffmann-La Roche Ag | Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase |
US6462060B2 (en) | 2000-08-18 | 2002-10-08 | Agouron Pharmaceuticals, Inc. | Heterocyclic-hydroxyimino-fluorene nuclei compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
US6462069B2 (en) | 2000-04-18 | 2002-10-08 | Agouron Pharmaceuticals, Inc. | Compounds, pharmaceutical compositions, and methods for inhibiting protein kinases |
WO2003000687A1 (en) * | 2001-06-22 | 2003-01-03 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
WO2003004467A2 (en) * | 2001-07-06 | 2003-01-16 | Agouron Pharmaceuticals, Inc. | Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use |
US6515004B1 (en) | 1999-12-15 | 2003-02-04 | Bristol-Myers Squibb Company | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
WO2003011843A1 (en) * | 2001-08-03 | 2003-02-13 | Novo Nordisk A/S | Novel 2,4-diaminothiazole derivatives |
US6531491B1 (en) | 1999-07-02 | 2003-03-11 | Agouron Pharamaceuticals, Inc. | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
US6555539B2 (en) | 2000-01-18 | 2003-04-29 | Agouron Pharmaceuticals | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
US6596746B1 (en) | 1999-04-15 | 2003-07-22 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
US6635641B2 (en) | 2000-01-21 | 2003-10-21 | Agouron Pharmaceuticals, Inc. | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
WO2003097048A1 (en) * | 2002-05-17 | 2003-11-27 | F. Hoffmann-La Roche Ag | Diaminothiazoles |
WO2004014884A1 (en) * | 2002-08-07 | 2004-02-19 | F. Hoffmann-La Roche Ag | Thiazole derivatives |
WO2004072070A1 (en) * | 2003-02-12 | 2004-08-26 | Pfizer Inc. | Antiproliferative 2-(sulfo-phenyl)-aminothiazole derivatives |
WO2004074283A1 (en) * | 2003-02-21 | 2004-09-02 | Pfizer Inc. | N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors |
WO2005002552A2 (en) | 2003-07-03 | 2005-01-13 | Astex Therapeutics Limited | Benzimidazole derivatives and their use as protein kinases inhibitors |
WO2005012256A1 (en) | 2003-07-22 | 2005-02-10 | Astex Therapeutics Limited | 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
US6869962B2 (en) | 2002-06-14 | 2005-03-22 | Agouron Pharmaceuticals, Inc. | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use |
US6872724B2 (en) | 2002-07-24 | 2005-03-29 | Merck & Co., Inc. | Polymorphs with tyrosine kinase activity |
EP1550372A1 (en) * | 2003-12-24 | 2005-07-06 | Bayer CropScience GmbH | Plant growth regulation |
WO2005097766A1 (en) * | 2004-03-31 | 2005-10-20 | Lexicon Genetics, Inc. | 2-aminomethylthiazole-5-carboxamides as protein kinase modulators |
WO2005103034A1 (en) * | 2004-04-20 | 2005-11-03 | F. Hoffman-La Roche Ag | Novel piperidine substituted diaminothiazoles |
WO2006005508A1 (en) * | 2004-07-15 | 2006-01-19 | F.Hoffmann-La Roche Ag | Novel 2,4-diaminothiazol-5-one derivatives |
WO2006005548A1 (en) * | 2004-07-15 | 2006-01-19 | F. Hoffmann-La Roche Ag | Novel 2,6-diaminopyridine-3-one derivatives |
WO2006077428A1 (en) | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Pharmaceutical compounds |
WO2006077424A1 (en) | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Pharmaceutical compounds |
EP1712550A2 (en) * | 2000-12-22 | 2006-10-18 | Ortho-McNeil Pharmaceutical, Inc. | Substituted triazole diamine derivatives as kinase inhibitors |
US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
EP1724270A2 (en) | 2001-07-19 | 2006-11-22 | Pfizer Italia S.r.l. | Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents |
US7141581B2 (en) | 1999-07-02 | 2006-11-28 | Agouron Pharmaceuticals, Inc. | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
US7157455B2 (en) | 2003-02-10 | 2007-01-02 | Hoffmann-La Roche Inc. | 4-Aminopyrimidine-5-one derivatives |
JP2007519711A (ja) * | 2004-01-30 | 2007-07-19 | アブ サイエンス | チロシンキナーゼ阻害薬としての2−(3−置換−アリール)アミノ−4−アリール−チアゾール |
US7247727B2 (en) | 2004-10-14 | 2007-07-24 | Hoffmann-La Roche Inc. | Azaindole thiazolinones |
US7294626B2 (en) | 2003-07-29 | 2007-11-13 | Novo Nordisk A/S | Piperazines |
US7304074B2 (en) | 2005-04-05 | 2007-12-04 | Hoffmann-La Roche Inc. | Substituted 1,5-naphthyridine azolinones |
JP2008513396A (ja) * | 2004-09-17 | 2008-05-01 | エフ.ホフマン−ラ ロシュ アーゲー | チアゾリノン4−単置換キノリン類 |
JP2008513398A (ja) * | 2004-09-17 | 2008-05-01 | エフ.ホフマン−ラ ロシュ アーゲー | 2位が置換されたチアゾリノン置換キノリン |
US7405220B2 (en) | 2004-06-09 | 2008-07-29 | Hoffmann-La Roche Inc. | Pyrazolopyrimidines |
US7585859B2 (en) | 2004-05-06 | 2009-09-08 | Plexxikon, Inc. | PDE4B inhibitors and uses therefor |
US7605168B2 (en) | 2004-09-03 | 2009-10-20 | Plexxikon, Inc. | PDE4B inhibitors |
US7652044B2 (en) | 2003-06-03 | 2010-01-26 | Novartis A.G. | P-38 inhibitors |
US7863314B2 (en) | 2003-06-26 | 2011-01-04 | Novartis Ag | 5-membered heterocycle-based p38 kinase inhibitors |
BG66070B1 (bg) * | 1999-07-02 | 2011-01-31 | Agouron Pharmaceuticals, Inc. | Индазолови съединения и фармацевтични състави за инхибиране на протеин кинази и методи за тяхното използване |
EP2301928A1 (en) | 2005-07-30 | 2011-03-30 | AstraZeneca AB | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders |
EP2395000A1 (en) | 2004-12-30 | 2011-12-14 | Astex Therapeutics Limited | Benzimidazole compounds that modulate the activity of CDK, GSK and aurora kinases |
US8318927B2 (en) | 2006-05-23 | 2012-11-27 | High Point Pharmaceuticals, Llc | 6-(4-cyclopropylpiperazin-1-yl)-2′-methyl-[3, 4′]-bipyridine and its uses as a medicament |
US8344001B2 (en) | 2007-06-11 | 2013-01-01 | High Point Pharmaceuticals, Llc | Heterocyclic H3 antagonists |
US8378097B2 (en) | 2006-05-29 | 2013-02-19 | High Point Pharmaceuticals, Llc | 3-(1,3-benzodioxol-5-yl)-6-(4-cyclopropylpiperazin-1-yl)-pyridazine, its salts and solvates and its use as histamine H3 receptor antagonist |
US8394842B2 (en) | 2006-03-28 | 2013-03-12 | High Point Pharmaceuticals, Llc | Benzothiazoles having histamine H3 receptor activity |
US8501739B2 (en) | 2005-07-04 | 2013-08-06 | High Point Pharmaceuticals, Llc | Medicaments |
WO2018089902A1 (en) * | 2016-11-13 | 2018-05-17 | Apogee Biotechnology Corporation | Diaminothiazole compounds, compositions and methods of use |
WO2018124001A1 (ja) | 2016-12-27 | 2018-07-05 | 国立研究開発法人理化学研究所 | Bmpシグナル阻害化合物 |
USRE47739E1 (en) | 2002-01-22 | 2019-11-26 | Warner-Lambert Company Llc | 2-(pyridin-2-ylamino)-pyrido[2,3-D]pyrimidin-7-ones |
EP3571196A4 (en) * | 2017-01-19 | 2020-08-12 | Temple University Of The Commonwealth System Of Higher Education | NOVEL BRIDGED BICYCLOALKYL SUBSTITUTED AMINOTHIZOLS AND METHOD OF USING THEM |
US10940149B1 (en) | 2018-06-15 | 2021-03-09 | Handa Oncology, Llc | Kinase inhibitor salts and compositions thereof |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2267873T3 (es) * | 1997-10-27 | 2007-03-16 | Agouron Pharmaceuticals, Inc. | Derivados de 4-aminotiazol, su preparacion y uso como inhibidores de kinasas dependientes de ciclina. |
AU2003281664A1 (en) | 2002-07-25 | 2004-02-16 | Pfizer Products Inc. | Isothiazole derivatives useful as anticancer agents |
WO2005047504A1 (en) * | 2003-11-07 | 2005-05-26 | The Board Of Trustees Of The University Of Illinois | Induction of cellular senescence by cdk4 disruption for tumor suppression and regression |
JP2007513967A (ja) * | 2003-12-11 | 2007-05-31 | セラヴァンス, インコーポレーテッド | 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物 |
JP2008526721A (ja) | 2004-12-30 | 2008-07-24 | アステックス、セラピューティックス、リミテッド | Cdk、gsk及びオーロラキナーゼの活性を調節するチアゾールおよびイソチアゾール誘導体 |
US7705009B2 (en) * | 2005-11-22 | 2010-04-27 | Hoffman-La Roche Inc. | 4-aminopyrimidine-5-thione derivatives |
ATE515506T1 (de) * | 2007-02-13 | 2011-07-15 | Ab Science | Verfahren zur synthese von 2- aminothiazolverbindungen als kinaseinhibitoren |
DE602008004769D1 (en) * | 2007-05-11 | 2011-03-10 | Hoffmann La Roche | Hetarylaniline als modulatoren für amyloid beta |
ES2685171T3 (es) | 2010-06-14 | 2018-10-05 | The Scripps Research Institute | Reprogramación de células a un nuevo destino |
EP3431087A1 (en) * | 2012-02-02 | 2019-01-23 | Senex Biotechnology, Inc. | Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventive methods for cancer |
CN102977049A (zh) * | 2012-11-26 | 2013-03-20 | 盛世泰科生物医药技术(苏州)有限公司 | 一种2-氨基-4-环丙基-5-羧酸乙酯噻唑的合成方法 |
JP2016523830A (ja) * | 2013-05-07 | 2016-08-12 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 放射線緩和薬学的配合物 |
CN104628627A (zh) * | 2014-12-23 | 2015-05-20 | 安徽德信佳生物医药有限公司 | 一种1-boc-4-氨基哌啶的合成方法 |
CN106854200B (zh) * | 2015-12-08 | 2019-05-21 | 上海复星星泰医药科技有限公司 | 色瑞替尼及其中间体的制备方法 |
CN109897014A (zh) * | 2019-04-17 | 2019-06-18 | 成都睿智化学研究有限公司 | 一种1-(取代苯基)-4-甲基哌嗪的工艺制备方法 |
CN114099503A (zh) * | 2020-09-01 | 2022-03-01 | 乔海灵 | 化合物作为cyp2e1抑制剂的应用 |
CN114805432A (zh) * | 2022-03-03 | 2022-07-29 | 西北工业大学 | 新型可光催化剪切的羧酸保护基及其氨基酸衍生物的制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992020642A1 (en) * | 1991-05-10 | 1992-11-26 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
WO1995015758A1 (en) * | 1993-12-10 | 1995-06-15 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit csf-1r receptor tyrosine kinase |
WO1996039145A1 (en) * | 1995-06-06 | 1996-12-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of her-2 autophosphorylation properties |
WO1998033798A2 (en) * | 1997-02-05 | 1998-08-06 | Warner Lambert Company | Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3530161A (en) | 1968-08-19 | 1970-09-22 | Shell Oil Co | Aromatic isothiocyanate production |
BE792402A (fr) | 1971-12-07 | 1973-06-07 | Ciba Geigy | Composes heterocycliques azotes et medicaments anthelminthiqueset antimicrobiens qui en contiennent |
CH593806A5 (xx) | 1974-11-14 | 1977-12-15 | Ciba Geigy Ag | |
US4086239A (en) | 1977-07-01 | 1978-04-25 | Stauffer Chemical Company | Thiazole bis-phosphates and phosphonates, intermediates, and insecticidal compositions and methods |
US4649146A (en) | 1983-01-31 | 1987-03-10 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole derivatives and pharmaceutical composition comprising the same |
DE3804531A1 (de) | 1988-02-13 | 1989-08-24 | Bayer Ag | 5-cyano-2,4-diamino-thiazol-derivate |
IE68593B1 (en) | 1989-12-06 | 1996-06-26 | Sanofi Sa | Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them |
US5620963A (en) | 1991-10-15 | 1997-04-15 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity |
JPH07502164A (ja) | 1991-09-20 | 1995-03-09 | フレッド ハッチンソン キャンサー リサーチ センター | ヒトサイクリンe |
US5262409A (en) | 1991-10-11 | 1993-11-16 | Fred Hutchinson Cancer Research Center | Binary tumor therapy |
US5441880A (en) | 1991-11-18 | 1995-08-15 | Cold Spring Harbor Laboratory | Human cdc25 genes, encoded products and uses thereof |
US5596079A (en) | 1991-12-16 | 1997-01-21 | Smith; James R. | Mimetics of senescent cell derived inhibitors of DNA synthesis |
US5302706A (en) | 1991-12-16 | 1994-04-12 | Baylor College Of Medicine | Senescent cell derived inhibitors of DNA synthesis |
WO1993021230A1 (en) | 1992-04-10 | 1993-10-28 | Dana-Farber Cancer Institute, Inc. | Activation-state-specific phosphoprotein immunodetection |
AU5168393A (en) | 1992-09-30 | 1994-04-26 | Yale University | Therapeutic and diagnostic methods and compositions based on transducin-like enhancer of split proteins and nucleic acids |
US5543291A (en) | 1993-01-29 | 1996-08-06 | Dana Farber Cancer Institute | Method of detecting carcinoma |
CA2162586C (en) | 1993-05-13 | 2006-01-03 | David J. Grainger | Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells |
US5443962A (en) | 1993-06-04 | 1995-08-22 | Mitotix, Inc. | Methods of identifying inhibitors of cdc25 phosphatase |
US5514571A (en) | 1993-08-05 | 1996-05-07 | University Technologies International Inc. | Cyclin D1 negative regulatory activity |
US5473056A (en) | 1993-10-13 | 1995-12-05 | Merck & Co., Inc. | E2F-2, a novel mammalian transcription factor |
US5532167A (en) | 1994-01-07 | 1996-07-02 | Beth Israel Hospital | Substrate specificity of protein kinases |
US5484710A (en) | 1994-01-14 | 1996-01-16 | La Jolla Cancer Research Foundation | Method of down-regulating a gene linked to a P-53 responsive element |
US5625031A (en) | 1994-02-08 | 1997-04-29 | Bristol-Myers Squibb Company | Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein |
AU685627B2 (en) | 1994-03-18 | 1998-01-22 | Myriad Genetics, Inc. | Germline mutations in the MTS gene and method for detecting predisposition to cancer at the MTS gene |
US5496831A (en) | 1994-05-13 | 1996-03-05 | The General Hospital Corporation | Inhibition of insulin-induced adiposis |
US5631156A (en) | 1994-06-21 | 1997-05-20 | The University Of Michigan | DNA encoding and 18 KD CDK6 inhibiting protein |
US5571523A (en) | 1995-03-09 | 1996-11-05 | President And Fellows Of Harvard College | Antioxidant-induced apoptosis in vascular smooth muscle cells |
US5733920A (en) | 1995-10-31 | 1998-03-31 | Mitotix, Inc. | Inhibitors of cyclin dependent kinases |
EP0874846B1 (en) | 1995-11-01 | 2003-04-02 | Novartis AG | Purine derivatives and processes for their preparation |
US5849733A (en) | 1996-05-10 | 1998-12-15 | Bristol-Myers Squibb Co. | 2-thio or 2-oxo flavopiridol analogs |
TW513418B (en) | 1996-07-31 | 2002-12-11 | Otsuka Pharma Co Ltd | Thiazole derivatives, their production and use |
DZ2285A1 (fr) | 1996-08-08 | 2002-12-25 | Smithkline Beecham Corp | Inhibiteurs de protéase de la cystéine. |
GB9621757D0 (en) | 1996-10-18 | 1996-12-11 | Ciba Geigy Ag | Phenyl-substituted bicyclic heterocyclyl derivatives and their use |
ES2267873T3 (es) * | 1997-10-27 | 2007-03-16 | Agouron Pharmaceuticals, Inc. | Derivados de 4-aminotiazol, su preparacion y uso como inhibidores de kinasas dependientes de ciclina. |
UA71971C2 (en) * | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
-
1998
- 1998-10-27 ES ES02001881T patent/ES2267873T3/es not_active Expired - Lifetime
- 1998-10-27 YU YU22400A patent/YU22400A/sh unknown
- 1998-10-27 SK SK521-2000A patent/SK5212000A3/sk unknown
- 1998-10-27 RO ROA200000423A patent/RO119463B1/ro unknown
- 1998-10-27 WO PCT/US1998/022809 patent/WO1999021845A2/en active IP Right Grant
- 1998-10-27 AU AU13664/99A patent/AU738792B2/en not_active Ceased
- 1998-10-27 BR BR9815200-9A patent/BR9815200A/pt not_active Application Discontinuation
- 1998-10-27 ES ES98957393T patent/ES2256968T3/es not_active Expired - Lifetime
- 1998-10-27 CA CA002306082A patent/CA2306082A1/en not_active Abandoned
- 1998-10-27 AP APAP/P/2000/001795A patent/AP1445A/en active
- 1998-10-27 NZ NZ503788A patent/NZ503788A/xx unknown
- 1998-10-27 UA UA2000042107A patent/UA66810C2/uk unknown
- 1998-10-27 EA EA200000464A patent/EA003527B1/ru not_active IP Right Cessation
- 1998-10-27 US US09/179,744 patent/US6569878B1/en not_active Expired - Fee Related
- 1998-10-27 JP JP2000517957A patent/JP2004500304A/ja active Pending
- 1998-10-27 TR TR2000/01081T patent/TR200001081T2/xx unknown
- 1998-10-27 SI SI9820068A patent/SI20324A/sl unknown
- 1998-10-27 GE GEAP19985301A patent/GEP20032896B/en unknown
- 1998-10-27 AT AT02001881T patent/ATE332896T1/de not_active IP Right Cessation
- 1998-10-27 DE DE69833223T patent/DE69833223T2/de not_active Expired - Fee Related
- 1998-10-27 CN CNB988104741A patent/CN1158269C/zh not_active Expired - Fee Related
- 1998-10-27 EP EP98957393A patent/EP1056732B1/en not_active Expired - Lifetime
- 1998-10-27 PL PL98342447A patent/PL342447A1/xx not_active Application Discontinuation
- 1998-10-27 EE EEP200000289A patent/EE200000289A/xx unknown
- 1998-10-27 IL IL13557498A patent/IL135574A0/xx unknown
- 1998-10-27 DE DE69835241T patent/DE69835241T2/de not_active Expired - Fee Related
- 1998-10-27 AT AT98957393T patent/ATE315553T1/de not_active IP Right Cessation
- 1998-10-27 KR KR1020007004392A patent/KR20010082501A/ko not_active Application Discontinuation
- 1998-10-27 HU HU0004512A patent/HUP0004512A3/hu unknown
- 1998-10-27 ID IDW20000740A patent/ID24372A/id unknown
-
2000
- 2000-04-14 LT LT2000033A patent/LT4855B/lt not_active IP Right Cessation
- 2000-04-14 NO NO20001955A patent/NO20001955L/no not_active Application Discontinuation
- 2000-04-17 HR HR20000222A patent/HRP20000222A2/hr not_active Application Discontinuation
- 2000-04-19 IS IS5462A patent/IS5462A/is unknown
- 2000-04-25 OA OA1200000120A patent/OA11352A/en unknown
- 2000-05-03 LV LVP-00-51A patent/LV12592B/en unknown
- 2000-05-26 BG BG104478A patent/BG64195B1/bg unknown
-
2003
- 2003-03-13 US US10/388,851 patent/US20030220326A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992020642A1 (en) * | 1991-05-10 | 1992-11-26 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
WO1995015758A1 (en) * | 1993-12-10 | 1995-06-15 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit csf-1r receptor tyrosine kinase |
WO1996039145A1 (en) * | 1995-06-06 | 1996-12-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of her-2 autophosphorylation properties |
WO1998033798A2 (en) * | 1997-02-05 | 1998-08-06 | Warner Lambert Company | Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation |
Non-Patent Citations (5)
Title |
---|
BINU R. ET AL.: "Synthesis and cyclization of 1-(N-nitroamidino)thioureas to 2,4-diaminothiazoles" ORGANIC PREPARATIONS AND PROCEDURES INTERNATIONAL, vol. 30, no. 1, 1998, pages 93-96, XP002095707 * |
GEWALD K. ET AL.: "4-Amino-thiazole" JOURNAL F]R PRAKTISCHE CHEMIE, vol. 35, no. 4, 1967, pages 97-104, XP002095703 cited in the application * |
JENARDANAN G.C. ET AL.: "1-(N-Arylthiocarbamoyl)amidino-3,5-dimeth ylpyrazoles - preparation and use in heterocycle synthesis" SYNTHETIC COMMUNICATIONS, vol. 27, no. 19, 1997, pages 3457-3462, XP002095706 * |
NESTEROV V.N. ET AL.: "Cyclization of nitriles. XXIV. Reactions of cyanamide derivatives of thiocarbamic acids with cyanothioacetamide. Crystal structure of 2-allylamino-4-amino-5-benzoyl-1,3-thiazol e" JOURNAL OF ORGANIC CHEMISTRY, USSR, vol. 24, no. 4, April 1988, pages 762-770, XP002095705 * |
RAJASEKHARAN K.N. ET AL.: "Studies on the synthesis of 5-acyl-2,4-diaminothiazoles from amidinothioureas" SYNTHESIS, vol. 5, 1986, pages 353-355, XP002095704 * |
Cited By (128)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7790902B2 (en) | 1998-06-04 | 2010-09-07 | Pfizer, Inc. | Isothiazole derivatives useful as anticancer agents |
US6235764B1 (en) | 1998-06-04 | 2001-05-22 | Pfizer Inc. | Isothiazole derivatives useful as anticancer agents |
US7405218B2 (en) | 1998-06-04 | 2008-07-29 | Pfizer, Inc. | Isothiazole derivatives useful as anticancer agents |
EP1122242A4 (en) * | 1998-09-22 | 2004-12-01 | Yamanouchi Pharma Co Ltd | Cyanophenyl DERIVATIVES |
EP1122242A1 (en) * | 1998-09-22 | 2001-08-08 | Yamanouchi Pharmaceutical Co. Ltd. | Cyanophenyl derivatives |
US6214852B1 (en) | 1998-10-21 | 2001-04-10 | Bristol-Myers Squibb Company | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
US6414156B2 (en) | 1998-10-21 | 2002-07-02 | Bristol-Myers Squibb Company | Process for preparing azacycloalkanoylaminothiazoles |
US7153856B2 (en) | 1999-04-15 | 2006-12-26 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
US6596746B1 (en) | 1999-04-15 | 2003-07-22 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
EP2308833A2 (en) * | 1999-04-15 | 2011-04-13 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
US7189854B2 (en) | 1999-04-15 | 2007-03-13 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
US6979694B2 (en) | 1999-04-15 | 2005-12-27 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
US8716323B2 (en) | 1999-04-15 | 2014-05-06 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
US7091223B2 (en) | 1999-04-15 | 2006-08-15 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
WO2000075120A1 (en) * | 1999-06-04 | 2000-12-14 | Agouron Pharmaceuticals, Inc. | Diaminothiazoles and their use for inhibiting protein kinases |
US6620828B2 (en) | 1999-06-04 | 2003-09-16 | Agouron Pharmaceuticals, Inc. | Thiazole compounds and pharmaceutical compositions for inhibiting protein kinases and methods for their use |
BG66070B1 (bg) * | 1999-07-02 | 2011-01-31 | Agouron Pharmaceuticals, Inc. | Индазолови съединения и фармацевтични състави за инхибиране на протеин кинази и методи за тяхното използване |
US6891044B2 (en) | 1999-07-02 | 2005-05-10 | Agouron Pharmaceuticals, Inc. | Indazole compounds and pharmaceutical compositions for Inhibiting protein kinases, and methods for their use |
US6884890B2 (en) | 1999-07-02 | 2005-04-26 | Agouron Pharmaceuticals, Inc. | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
US7141587B2 (en) | 1999-07-02 | 2006-11-28 | Agouron Pharmaceuticals, Inc. | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
US6531491B1 (en) | 1999-07-02 | 2003-03-11 | Agouron Pharamaceuticals, Inc. | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
US6534524B1 (en) | 1999-07-02 | 2003-03-18 | Agouron Pharmaceuticals, Inc. | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
US7141581B2 (en) | 1999-07-02 | 2006-11-28 | Agouron Pharmaceuticals, Inc. | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
HRP20020127B1 (en) * | 1999-08-12 | 2010-08-31 | Pharmacia Italia S.P.A. | Arylmethyl-carbonylamino-thiazole and their use as antitumor agents |
WO2001014353A1 (en) * | 1999-08-12 | 2001-03-01 | Pharmacia Italia, S.P.A. | Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents |
US6784198B1 (en) | 1999-08-12 | 2004-08-31 | Pharmacia Italia S.P.A. | Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents |
EA005375B1 (ru) * | 1999-08-12 | 2005-02-24 | Фармация Италия, С.П.А. | Производные арилметилкарбониламинотиазола и их применение в качестве противоопухолевых средств |
JP4864260B2 (ja) * | 1999-08-12 | 2012-02-01 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | アリールメチル−カルボニルアミノ−チアゾール誘導体及び抗腫瘍薬としてのその使用 |
CZ303138B6 (cs) * | 1999-08-12 | 2012-04-25 | Nerviano Medical Sciences S.R.L. | Arylmethylkarbonylaminothiazolové deriváty a jejich použití jako protinádorová cinidla |
CN100410245C (zh) * | 1999-08-12 | 2008-08-13 | 法玛西雅意大利公司 | 芳基甲基-羰基氨基-噻唑衍生物及其作为抗肿瘤剂的用途 |
JP2003507461A (ja) * | 1999-08-12 | 2003-02-25 | フアルマシア・イタリア・エツセ・ピー・アー | アリールメチル−カルボニルアミノ−チアゾール誘導体及び抗腫瘍薬としてのその使用 |
US6639074B2 (en) | 1999-12-15 | 2003-10-28 | Bristol Myers Squibb Company | Process for preparing azacycloalkanoylaminothiazoles |
US6515004B1 (en) | 1999-12-15 | 2003-02-04 | Bristol-Myers Squibb Company | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
US6392053B2 (en) | 1999-12-15 | 2002-05-21 | Bristol-Myers Squibb Company | Process for preparing arylacetylaminothiazoles |
US6613911B2 (en) | 1999-12-15 | 2003-09-02 | Bristol-Myers Squibb Company | Process for preparing arylacetylaminothiazoles |
US6555539B2 (en) | 2000-01-18 | 2003-04-29 | Agouron Pharmaceuticals | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
US6635641B2 (en) | 2000-01-21 | 2003-10-21 | Agouron Pharmaceuticals, Inc. | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
WO2001056567A1 (en) * | 2000-02-04 | 2001-08-09 | Novo Nordisk A/S | 2,4-diaminothiazole derivatives and their use as glycogen synthase kinase-3 (gsk-3) inhibitors |
US6462069B2 (en) | 2000-04-18 | 2002-10-08 | Agouron Pharmaceuticals, Inc. | Compounds, pharmaceutical compositions, and methods for inhibiting protein kinases |
WO2001085726A1 (en) * | 2000-05-10 | 2001-11-15 | Lg Life Sciences Ltd. | Indazoles substituted with 1,1-dioxoisothiazolidine useful as inhibitors of cell proliferation |
US6620831B2 (en) | 2000-05-10 | 2003-09-16 | Lg Life Sciences Ltd. | Indazoles substituted with 1,1-dioxoisothiazolidine useful as inhibitors of cell proliferation |
US6566363B2 (en) | 2000-08-09 | 2003-05-20 | Agouron Pharmaceuticals, Inc. | Pyrazole-thiazole compounds, pharmaceutical compositions containing them |
WO2002012250A2 (en) * | 2000-08-09 | 2002-02-14 | Agouron Pharmaceuticals, Inc. | Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases |
WO2002012250A3 (en) * | 2000-08-09 | 2002-09-06 | Agouron Pharma | Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases |
US6462060B2 (en) | 2000-08-18 | 2002-10-08 | Agouron Pharmaceuticals, Inc. | Heterocyclic-hydroxyimino-fluorene nuclei compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
US7317031B2 (en) | 2000-12-22 | 2008-01-08 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted triazole diamine derivatives as kinase inhibitors |
WO2002057240A1 (en) * | 2000-12-22 | 2002-07-25 | Ortho Mc Neil Pharmaceutical, Inc. | Substituted triazole diamine derivatives as kinase inhibitors |
US6924302B2 (en) | 2000-12-22 | 2005-08-02 | Ortho Mcneil Pharmaceutical, Inc. | Substituted triazole diamine derivatives as kinase inhibitors |
EP1712550A3 (en) * | 2000-12-22 | 2009-07-15 | Ortho-McNeil Pharmaceutical, Inc. | Substituted triazole diamine derivatives as kinase inhibitors |
EP1712550A2 (en) * | 2000-12-22 | 2006-10-18 | Ortho-McNeil Pharmaceutical, Inc. | Substituted triazole diamine derivatives as kinase inhibitors |
CN100357278C (zh) * | 2000-12-22 | 2007-12-26 | 奥索-麦克尼尔药品公司 | 作为激酶抑制剂的取代的***二胺衍生物 |
AU2002242687B2 (en) * | 2001-01-22 | 2007-05-10 | F. Hoffmann-La Roche Ag | Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase |
WO2002057261A2 (en) * | 2001-01-22 | 2002-07-25 | F. Hoffmann-La Roche Ag | Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase |
US6756374B2 (en) | 2001-01-22 | 2004-06-29 | Hoffmann-La Roche Inc. | Diaminothiazoles having antiproliferative activity |
WO2002057261A3 (en) * | 2001-01-22 | 2002-10-17 | Hoffmann La Roche | Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase |
US7105670B2 (en) | 2001-01-22 | 2006-09-12 | Hoffmann-La Roche Inc. | Intermediates useful in the preparation of diaminothiazoles |
US7094896B2 (en) | 2001-01-22 | 2006-08-22 | Hoffmann-La Roche Inc. | Diaminothiazoles having antiproliferative activity |
WO2003000687A1 (en) * | 2001-06-22 | 2003-01-03 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US6720346B2 (en) * | 2001-07-06 | 2004-04-13 | Agouron Pharmaceuticals, Inc. | Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation |
WO2003004467A2 (en) * | 2001-07-06 | 2003-01-16 | Agouron Pharmaceuticals, Inc. | Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use |
WO2003004467A3 (en) * | 2001-07-06 | 2004-05-06 | Agouron Pharma | Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use |
EP1724270A2 (en) | 2001-07-19 | 2006-11-22 | Pfizer Italia S.r.l. | Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents |
WO2003011843A1 (en) * | 2001-08-03 | 2003-02-13 | Novo Nordisk A/S | Novel 2,4-diaminothiazole derivatives |
USRE47739E1 (en) | 2002-01-22 | 2019-11-26 | Warner-Lambert Company Llc | 2-(pyridin-2-ylamino)-pyrido[2,3-D]pyrimidin-7-ones |
AU2003232754B2 (en) * | 2002-05-17 | 2009-03-12 | F. Hoffmann-La Roche Ag | Diaminothiazoles |
WO2003097048A1 (en) * | 2002-05-17 | 2003-11-27 | F. Hoffmann-La Roche Ag | Diaminothiazoles |
CN100400041C (zh) * | 2002-05-17 | 2008-07-09 | 霍夫曼-拉罗奇有限公司 | 可以用作cdk4选择性抑制剂的二氨基噻唑类化合物 |
US6869962B2 (en) | 2002-06-14 | 2005-03-22 | Agouron Pharmaceuticals, Inc. | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use |
US7045528B2 (en) | 2002-06-14 | 2006-05-16 | Agouron Pharmaceuticals, Inc. | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use |
US6872724B2 (en) | 2002-07-24 | 2005-03-29 | Merck & Co., Inc. | Polymorphs with tyrosine kinase activity |
US7253197B2 (en) | 2002-08-07 | 2007-08-07 | Hoffmann-La Roche Inc. | Aminothiazole derivatives |
WO2004014884A1 (en) * | 2002-08-07 | 2004-02-19 | F. Hoffmann-La Roche Ag | Thiazole derivatives |
US7157455B2 (en) | 2003-02-10 | 2007-01-02 | Hoffmann-La Roche Inc. | 4-Aminopyrimidine-5-one derivatives |
US7615634B2 (en) | 2003-02-10 | 2009-11-10 | Hoffmann-La Roche Inc. | 4-aminopyrimidine-5-one derivatives |
WO2004072070A1 (en) * | 2003-02-12 | 2004-08-26 | Pfizer Inc. | Antiproliferative 2-(sulfo-phenyl)-aminothiazole derivatives |
WO2004074283A1 (en) * | 2003-02-21 | 2004-09-02 | Pfizer Inc. | N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors |
US7652044B2 (en) | 2003-06-03 | 2010-01-26 | Novartis A.G. | P-38 inhibitors |
US8242117B2 (en) | 2003-06-26 | 2012-08-14 | Novartis Ag | 5-membered heterocycle-based p38 kinase inhibitors |
US7863314B2 (en) | 2003-06-26 | 2011-01-04 | Novartis Ag | 5-membered heterocycle-based p38 kinase inhibitors |
US8580838B2 (en) | 2003-06-26 | 2013-11-12 | Novartis Ag | 5-membered heterocycle-based p38 kinase inhibitors |
US8410160B2 (en) | 2003-06-26 | 2013-04-02 | Novartis Ag | 5-membered heterocycle-based P38 kinase inhibitors |
WO2005002552A2 (en) | 2003-07-03 | 2005-01-13 | Astex Therapeutics Limited | Benzimidazole derivatives and their use as protein kinases inhibitors |
EP2305250A1 (en) | 2003-07-03 | 2011-04-06 | Astex Therapeutics Limited | Benzimidazole derivatives and their use as protein kinases inhibitors |
EP2256106A1 (en) | 2003-07-22 | 2010-12-01 | Astex Therapeutics Limited | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators |
WO2005012256A1 (en) | 2003-07-22 | 2005-02-10 | Astex Therapeutics Limited | 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
US7294626B2 (en) | 2003-07-29 | 2007-11-13 | Novo Nordisk A/S | Piperazines |
EP1550372A1 (en) * | 2003-12-24 | 2005-07-06 | Bayer CropScience GmbH | Plant growth regulation |
JP2007519711A (ja) * | 2004-01-30 | 2007-07-19 | アブ サイエンス | チロシンキナーゼ阻害薬としての2−(3−置換−アリール)アミノ−4−アリール−チアゾール |
WO2005097766A1 (en) * | 2004-03-31 | 2005-10-20 | Lexicon Genetics, Inc. | 2-aminomethylthiazole-5-carboxamides as protein kinase modulators |
US7179827B2 (en) | 2004-03-31 | 2007-02-20 | Lexicon Genetics Incorporated | Thiazoles and methods of their use |
WO2005103034A1 (en) * | 2004-04-20 | 2005-11-03 | F. Hoffman-La Roche Ag | Novel piperidine substituted diaminothiazoles |
US7211576B2 (en) | 2004-04-20 | 2007-05-01 | Hoffmann-La Roche Inc. | Diaminothiazoles |
KR100832280B1 (ko) * | 2004-04-20 | 2008-05-26 | 에프. 호프만-라 로슈 아게 | 신규한 피페리딘 치환된 디아미노티아졸 |
US8470821B2 (en) | 2004-05-06 | 2013-06-25 | Plexxikon Inc. | PDE4B inhibitors and uses therefor |
US7585859B2 (en) | 2004-05-06 | 2009-09-08 | Plexxikon, Inc. | PDE4B inhibitors and uses therefor |
US7405220B2 (en) | 2004-06-09 | 2008-07-29 | Hoffmann-La Roche Inc. | Pyrazolopyrimidines |
WO2006005548A1 (en) * | 2004-07-15 | 2006-01-19 | F. Hoffmann-La Roche Ag | Novel 2,6-diaminopyridine-3-one derivatives |
US7423051B2 (en) | 2004-07-15 | 2008-09-09 | Hoffmann-La Roche Inc. | 2,6-diaminopyridine derivatives |
KR100853973B1 (ko) * | 2004-07-15 | 2008-08-25 | 에프. 호프만-라 로슈 아게 | 신규 2,6-디아미노피리딘-3-온 유도체 |
KR100908591B1 (ko) * | 2004-07-15 | 2009-07-22 | 에프. 호프만-라 로슈 아게 | 신규 2,4-디아미노티아졸-5-온 유도체 |
WO2006005508A1 (en) * | 2004-07-15 | 2006-01-19 | F.Hoffmann-La Roche Ag | Novel 2,4-diaminothiazol-5-one derivatives |
US7423053B2 (en) | 2004-07-15 | 2008-09-09 | Hoffmann-La Roche Inc. | 4-Aminothiazole derivatives |
US7605168B2 (en) | 2004-09-03 | 2009-10-20 | Plexxikon, Inc. | PDE4B inhibitors |
JP2008513398A (ja) * | 2004-09-17 | 2008-05-01 | エフ.ホフマン−ラ ロシュ アーゲー | 2位が置換されたチアゾリノン置換キノリン |
JP2008513396A (ja) * | 2004-09-17 | 2008-05-01 | エフ.ホフマン−ラ ロシュ アーゲー | チアゾリノン4−単置換キノリン類 |
US7247727B2 (en) | 2004-10-14 | 2007-07-24 | Hoffmann-La Roche Inc. | Azaindole thiazolinones |
EP2395000A1 (en) | 2004-12-30 | 2011-12-14 | Astex Therapeutics Limited | Benzimidazole compounds that modulate the activity of CDK, GSK and aurora kinases |
WO2006077428A1 (en) | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Pharmaceutical compounds |
WO2006077424A1 (en) | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Pharmaceutical compounds |
US7304074B2 (en) | 2005-04-05 | 2007-12-04 | Hoffmann-La Roche Inc. | Substituted 1,5-naphthyridine azolinones |
US8846677B2 (en) | 2005-07-04 | 2014-09-30 | High Point Pharmaceuticals, Llc | Medicaments |
US8501739B2 (en) | 2005-07-04 | 2013-08-06 | High Point Pharmaceuticals, Llc | Medicaments |
EP2301928A1 (en) | 2005-07-30 | 2011-03-30 | AstraZeneca AB | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders |
US8772285B2 (en) | 2006-03-28 | 2014-07-08 | High Point Pharmaceuticals, Llc | Benzothiazoles having histamine H3 receptor activity |
US8394842B2 (en) | 2006-03-28 | 2013-03-12 | High Point Pharmaceuticals, Llc | Benzothiazoles having histamine H3 receptor activity |
US8318927B2 (en) | 2006-05-23 | 2012-11-27 | High Point Pharmaceuticals, Llc | 6-(4-cyclopropylpiperazin-1-yl)-2′-methyl-[3, 4′]-bipyridine and its uses as a medicament |
US8378097B2 (en) | 2006-05-29 | 2013-02-19 | High Point Pharmaceuticals, Llc | 3-(1,3-benzodioxol-5-yl)-6-(4-cyclopropylpiperazin-1-yl)-pyridazine, its salts and solvates and its use as histamine H3 receptor antagonist |
US8344001B2 (en) | 2007-06-11 | 2013-01-01 | High Point Pharmaceuticals, Llc | Heterocyclic H3 antagonists |
WO2018089902A1 (en) * | 2016-11-13 | 2018-05-17 | Apogee Biotechnology Corporation | Diaminothiazole compounds, compositions and methods of use |
WO2018124001A1 (ja) | 2016-12-27 | 2018-07-05 | 国立研究開発法人理化学研究所 | Bmpシグナル阻害化合物 |
EP3571196A4 (en) * | 2017-01-19 | 2020-08-12 | Temple University Of The Commonwealth System Of Higher Education | NOVEL BRIDGED BICYCLOALKYL SUBSTITUTED AMINOTHIZOLS AND METHOD OF USING THEM |
US10941126B2 (en) | 2017-01-19 | 2021-03-09 | Temple University-Of The Commonwealth System Of Higher Education | Bridged bicycloalkyl-substituted aminothiazoles and their methods of use |
EP4219486A1 (en) * | 2017-01-19 | 2023-08-02 | Temple University of the Commonwealth System of Higher Education | Novel bridged bicycloalkyl-substituted aminothizoles and their methods of use |
US10940149B1 (en) | 2018-06-15 | 2021-03-09 | Handa Oncology, Llc | Kinase inhibitor salts and compositions thereof |
US11007195B2 (en) | 2018-06-15 | 2021-05-18 | Handa Oncology, Llc | Kinase inhibitor salts, and compositions thereof |
US11052088B2 (en) | 2018-06-15 | 2021-07-06 | Handa Oncology, Llc | Kinase inhibitor salts, and compositions thereof |
US11160805B2 (en) | 2018-06-15 | 2021-11-02 | Handa Onocology, Llc | Kinase inhibitor salts and compositions thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6569878B1 (en) | Substituted 4-amino-thiazol-2-yl compounds as cyclin-dependent kinase inhibitors | |
CA2452609A1 (en) | Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use | |
DE602004011199T2 (de) | 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren | |
EP1300401B1 (en) | Thiazole derivatives for use as antiinflammatories | |
US20020025976A1 (en) | Thiazole compounds and pharmaceutical compositions for inhibiting protein kinases and methods for their use | |
HU210870A9 (en) | Pyrazolopyrimidinone antianginal agents | |
EP1215208A2 (en) | 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases | |
US6566363B2 (en) | Pyrazole-thiazole compounds, pharmaceutical compositions containing them | |
NZ517419A (en) | 4-aminothiazole derivatives and their use as inhibitors of cyclin-dependent kinases | |
MXPA00003812A (en) | 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases | |
US20040176431A1 (en) | Antiproliferative 2-(sulfo-phenyl)-aminothiazole derivatives and pharmaceutical compositions, and methods for their use | |
CZ20001285A3 (cs) | Substituované 4-aminothiazol-2-ylové sloučeniny jako inhibitory cyklin-dependentních kinas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 135574 Country of ref document: IL Ref document number: P-224/00 Country of ref document: YU Ref document number: 98810474.1 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 503788 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2000-1285 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5212000 Country of ref document: SK |
|
ENP | Entry into the national phase |
Ref document number: 2306082 Country of ref document: CA Ref document number: 2306082 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13664/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000033 Country of ref document: LT |
|
WWE | Wipo information: entry into national phase |
Ref document number: P20000222A Country of ref document: HR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/003812 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2000 200000423 Country of ref document: RO Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2000 517957 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000/01081 Country of ref document: TR Ref document number: 1200000357 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007004392 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2000 20000051 Country of ref document: LV Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200020000051 Country of ref document: LV |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998957393 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200000464 Country of ref document: EA |
|
WWP | Wipo information: published in national office |
Ref document number: 1998957393 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV2000-1285 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 2000033 Country of ref document: LT |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007004392 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000033 Country of ref document: LT |
|
WWG | Wipo information: grant in national office |
Ref document number: 13664/99 Country of ref document: AU |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020007004392 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998957393 Country of ref document: EP |